Beyond cancer: The Right to be Forgotten The Lancet Oncology ++... ++

Beyond cancer: The Right to be Forgotten The Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00399-2/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 27Number 9p1057-1192, e403-e439 https://www.thelancet.com/journals/lanonc/issue/vol27no9/PIIS1470-2045(26)X2008-3 Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus Prof Jean-Michel Hannoun-Levi, MD PhDa Send email to jean-michel.hannoun-levi@nice.unicancer.fr ∙ Prof Julie A Margenthaler, MDb ∙ Bethany Anderson, MD PhDc ∙ Rosa Di Micco, MD PhDd ∙ Prof Douglas W Arthur, MDe ∙ Prof Marianne Aznar, PhDf ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00177-4/abstract?dgcid=raven_jbs_etoc_feature_lanonc Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study Prof Masatoshi Kudo, MD PhDa,* Send email to mkudo@med.kindai.ac.jp ∙ Prof Ghassan K Abou-Alfa, MDb,c,d,* Send email to abou-alg@mskcc.org ∙ Prof Zhenggang Ren, MDe ∙ Prof Jeong Heo, MD PhDf ∙ Prof Riccardo Lencioni, MDg ∙ Yasuaki Arai, MDh ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00278-0/abstract?dgcid=raven_jbs_etoc_feature_lanonc